Search

Displaying results 3911 - 3920 of 5897 in total
  1. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade. … It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function.

  2. Drug

    VXA-CoV2-1

    go.drugbank.com/drugs/DB16433
    Investigational

    This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell … responses to both vaccine antigens of the SARS-CoV-2 nucleocapsid and spike proteins[L30498].

  3. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.

  4. Drug

    TO-901317

    go.drugbank.com/drugs/DB07080
    Experimental

    TO-901317 is an LXRalpha and LXRbeta agonist.

  5. Drug

    Lortalamine

    go.drugbank.com/drugs/DB09187
    Experimental

    This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.

  6. Drug

    (Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide

    go.drugbank.com/drugs/DB06941
    Experimental

    This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.

  7. Drug

    Cinaciguat

    go.drugbank.com/drugs/DB16126
    Investigational

    Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients

  8. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

  9. Drug

    2-Methoxyestradiol

    go.drugbank.com/drugs/DB02342
    Investigational

    2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis).

  10. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. … Preclinical studies of DDP733 established the compound’s prokinetic properties (the ability to promote the motility of the GI tract).